Top 20 Biotech Venture Capital Deals of 2009

With the help of data provided by the National Venture Capital Association, our sister pub FierceBiotech has put together a list of last year's top biotech venture capital deals. 2009 was an incredibly difficult year for biotech companies to raise venture funding, as the financial crisis caused firms to become more cautious with their money. But for companies with groundbreaking technology and exciting programs, there was still money to be had. Take a look at this list of the top 20 U.S. companies that raised big money in 2009. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.